Pubchem was able to locate a Bioassay completed by Dimitris Georgidis and Anthanasios Yiotakis  The study looked at specific targeting of metzincin family members with small molecule inhibitors. Discovery a target specific inhibitor for the ADAM33 could be an important step in treatment for patients with Asthmatic conditions due to ADAM33. Unfortunately, all advanced clinical trials with chemicals that have inhibitory properties in ADAM33 have been discontinued mainly due to unwanted side-effects such as tendonitis and fibroplasia.  Two small molecules were found to have inhibitory properties with ADAM33.
- Dimitris Georgiadis, Athanasios Yiotakis. Specific targeting of metzincin family members with small-molecule inhibitors: Progress toward a multifarious challenge. Bioorganic & Medicinal Chemistry Volume 16, Issue 19, 1 October 2008, Pages 8781-8794